|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor显示文摘In order to further promote the standardization of diagnosis and treatment of gastrointestinal stromal tumor(GIST) in China, the members of Chinese Society of Clinical Oncology(CSCO) Expert Committee on GIST thoroughly discussed the key contents of the consensus guidelines, and voted on the controversial issue. In final, the Chinese consensus guidelines for the diagnosis and management of GIST(2017 edition) was formed on the basis of 2013 edition consensus guidelines, which is hereby announced. The consensus included the pathological diagnosis,recurrence risk classification evaluation, targeted agent therapy, surgery and principles of surveillance of GIST. | jian li yingjiang ye jian wang bo zhang shukui qin yingqiang shi yulong he xiaobo liang xiufeng liu ye zhou xin wu xinhua zhang ming wang zhidong gao tianlong lin hui cao lin shen | 2017 | Chinese Journal of Cancer Research2017，29，4： | 104 |
| 2 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 23 |
| 3 | XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer显示文摘DNA 修理能力(DRC ) 向基于铂的化疗与癌症房间的敏感被相关。我们假设那在 DNA 的基因多型性修理基因 XPA (干皮病 pigmentosum 组 A )和 XPG (干皮病 pigmentosum 组 G )( ERCC5 ,切除修理跨互补的组 5 ),它在 DNA 修理效率导致内部个人的差别,可以在先进非小的房间肺癌症( NSCLC )预言临床的反应到铂代理人病人。在这研究,我们发现 XPA A23G 多型性的 A G 变化显著地增加了反应到基于铂的化疗。在 XPG His46His 的多型性与减少的治疗回答被联系,但是不是统计上重要的。 | Jifeng Feng Xinchen Sun Ning Sun Shukui Qin Fan Li Hongyan Cheng Baoan Chen YuanDong Cao Jun Ma Lu Cheng Zuhong Lu Jiazhong Ji Yingfeng Zhou | 2009 | Acta Biochimica et Biophysica Sinica2009，41，5： | 8 |
| 4 | Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)显示文摘 | Lin Shen Jin Li Jianming Xu Hongming Pan Guanghai Dai Shukui Qin Liwei Wang Jinwan Wang Zhenzhou Yang Yongqian Shu Ruihua Xu Lei Chen Yunpeng Liu Shiying Yu Lilian Bu Yongzhe Piao | 2015 | Gastric Cancer2015，，1： | 7 |
| 5 | Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer:a subpopulation analysis of the JACOB trial显示文摘Background:The JACOB trial(NCT01774786)was a double-blinded,placebo-controlled,randomized,multicenter,international,phase III trial evaluating the efficacy and safety of adding pertuzumab to trastuzumab and chemo-therapy in first-line treatment of human epidermal growth factor receptor 2(HER2)-positive metastatic gastric cancer/gastroesophageal junction cancer(GEJC).The aim of this analysis was to investigate efficacy and safety outcomes in the Chinese subpopulation from the JACOB trial.Methods:This post hoc subpopulation analysis included all patients recruited in China's Mainland(n=163;20.9%)between June 2013 and January 2016.The patients were randomly assigned in a 1:1 ratio to receive pertuzumab plus trastuzumab and chemotherapy(pertuzumab group;n=82)or placebo plus trastuzumab and chemotherapy(con-trol group;n=81).Intravenous pertuzumab(840 mg)and trastuzumab(8 mg/kg loading and 6 mg/kg maintenance doses)were given every 3 weeks until disease progression or unacceptable toxicity.Chemotherapy was given as per standard regimens/doses of capecitabine or 5-fluorouracil plus cisplatin.The primary endpoint was overall survival(OS);secondary efficacy endpoints included progression-free survival(PFS),and overall objective response rate(ORR).Results:The median OS was 18.7 months in the pertuzumab group and 16.1 months in the control group(hazard ratio[HR]0.75;95%confidence interval[CI]0.49 to 1.14).The median PFS was 10.5 and 8.6 months in the pertuzumab and control groups,respectively(HR 0.85;95%CI 0.60 to 1.21),and the median ORRs were 68.9%and 55.7%,respectively.The treatment effect in this Chinese subpopulation showed consistency with that in the global ITT population with numerically lower HR for OS and PFS compared with the control group.The safety profiles of the pertuzumab and control groups in this Chinese subpopulation analysis were generally comparable.The most common grade 3-5adverse events were neutropenia,anemia,and leukopenia.However,due to the nature of being a post hoc subgroup analysis,the results presented here are descriptive only and need to be interpreted with caution.Conclusions:OS and PFS were numerically improved by adding pertuzumab to trastuzumab and chemotherapy as first-line treatment in Chinese HER2-positive gastric cancer/GEJC patients,and this regimen demonstrated an acceptable safety profile. | Tianshu Liu Yanru Qin Jin Li Ruihua Xu Jianming Xu Shujun Yang Shukui Qin Yuxian Bai Changping Wu Yixiang Mao Haiyan Wu Yilin Ge Lin Shen | 2019 | Cancer Communications2019，39，1： | 6 |
| 6 | Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia显示文摘 | Shukui Qin Yuxian Bai Ho Yeong Lim Sumitra Thongprasert Yee Chao Jia Fan Tsai-Shen Yang Vajarabhongsa Bhudhisawasdi Won Ki Kang Yu Zhou Jee Hyun Lee Yan Sun | 2013 | Journal of Clinical Oncology2013，，28： | 5 |
| 7 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial显示文摘 | Ann-Lii Cheng Zhongzhen Guan Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Tsai-Sheng Yang Won Young Tak Hongming Pan Shiying Yu Jianming Xu Fang Fang Jessie Zou Giuseppe Lentini Dimitris Voliotis Yoon-Koo Kang | 2011 | European Journal of Cancer2011，，10： | 4 |
| 8 | Chinese expert consensus on conversion therapy for hepatocellular carcinoma(2021 edition)显示文摘Recent advances in systemic and locoregional treatments for patients with unresectable or advanced hepatocellular carcinoma(HCC)have resulted in improved response rates.This has provided an opportunity for selected patients with initially unresectable HCC to achieve adequate tumor downstaging to undergo surgical resection,a‘conversion therapy’strategy.However,conversion therapy is a new approach to the treatment of HCC and its practice and treatment protocols are still being developed.Review the evidence for conversion therapy in HCC and develop consensus statements to guide clinical practice.Evidence review:Many research centers in China have accumulated significant experience implementing HCC conversion therapy.Preliminary findings and data have shown that conversion therapy represents an important strategy to maximize the survival of selected patients with intermediate stage to advanced HCC;however,there are still many urgent clinical and scientific challenges for this therapeutic strategy and its related fields.In order to summarize and learn from past experience and review current challenges,the Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma(2021 Edition)was developed based on a review of preliminary experience and clinical data from Chinese and non-Chinese studies in this field and combined with recommendations for clinical practice.Sixteen consensus statements on the implementation of conversion therapy for HCC were developed.The statements generated in this review are based on a review of clinical evidence and real clinical experience and will help guide future progress in conversion therapy for patients with HCC. | Hui-Chuan Sun Jian Zhou Zheng Wang Xiufeng Liu Qing Xie Weidong Jia Ming Zhao Xinyu Bi Gong Li Xueli Bai Yuan Ji Li Xu Xiao-Dong Zhu Dousheng Bai Yajin Chen Yongjun Chen Chaoliu Dai Rongping Guo Wenzhi Guo Chunyi Hao Tao Huang Zhiyong Huang Deyu Li Gang Li Tao Li Xiangcheng Li Guangming Li Xiao Liang Jingfeng Liu Fubao Liu Shichun Lu Zheng Lu Weifu Lv Yilei Mao Guoliang Shao Yinghong Shi Tianqiang Song Guang Tan Yunqiang Tang Kaishan Tao Chidan Wan Guangyi Wang Lu Wang Shunxiang Wang Tianfu Wen Baocai Xing Bangde Xiang Sheng Yan Dinghua Yang Guowen Yin Tao Yin Zhenyu Yin Zhengping Yu Bixiang Zhang Jialin Zhang Shuijun Zhang Ti Zhang Yamin Zhang Yubao Zhang Aibin Zhang Haitao Zhao Ledu Zhou Wu Zhang Zhenyu Zhu Shukui Qin Feng Shen Xiujun Cai Gaojun Teng Jianqiang Cai Minshan Chen Qiang Li Lianxin Liu Weilin Wang Tingbo Liang Jiahong Dong Xiaoping Chen Xuehao Wang Shusen Zheng Jia Fan 无 | 2022 | Hepatobiliary Surgery and Nutrition2022，11，2： | 4 |
| 9 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 3 |
| 10 | Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia显示文摘 | Shukui Qin Yuxian Bai Ho Yeong Lim Sumitra Thongprasert Yee Chao Jia Fan Tsai-Shen Yang Vajarabhongsa Bhudhisawasdi Won Ki Kang Yu Zhou Jee Hyun Lee Yan Sun | 2013 | Journal of Clinical Oncology2013，，28： | 2 |
| 11 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 12 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 13 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 14 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 15 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 16 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 17 | Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia显示文摘 | Shukui Qin Yuxian Bai Ho Yeong Lim Sumitra Thongprasert Yee Chao Jia Fan Tsai-Shen Yang Vajarabhongsa Bhudhisawasdi Won Ki Kang Yu Zhou Jee Hyun Lee Yan Sun | 2013 | Journal of Clinical Oncology2013，，28： | 1 |
| 18 | Proteomic-based Analysis for Identification of Proteins Involved in 5-fluorouracil Resistance in Hepatocellular Carcinoma显示文摘 | Yi Tan Shukui Qin Xin Hou Xiujuan Qian Jun Xia Yumei Li Rui Wang Changjie Chen Qingling Yang Lucio Miele Qiong Wu Zhiwei Wang | 2014 | Current Pharmaceutical Design2014，，1： | 1 |
| 19 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 20 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员